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ABSTRACT:
Antibodies are considered as ‘magic bullets’ because of their high specificity. It is 
believed that antibodies are too large to routinely enter the cytosol, thus antibody 
therapeutic approach has been limited to extracellular or secreted proteins expressed 
by cancer cells. However, many oncogenic proteins are localized within the cell. 
To explore the possibility of antibody therapies against intracellular targets, we 
generated a chimeric antibody targeting the intracellular PRL-3 oncoprotein to 
assess its antitumor activities in mice. Remarkably, we observed that the PRL-3 
chimeric antibody could efficiently and specifically reduce the formation of PRL-3 
expressing metastatic tumors. We further found that natural killer (NK) cells were 
important in mediating the therapeutic effect, which was only observed in a nude 
mouse model (T-cell deficient), but not in a Severe Combined Immunodeficiency’ 
(scid) mouse model (B- and T-cell deficient), indicating the anticancer effect also 
depends on host B-cell activity. Our study involving 377 nude and scid mice suggests 
that antibodies targeting intracellular proteins can be developed to treat cancer.
INTRODUCTION
A century ago, Paul Ehrlich proposed the concept 
of antibodies as ‘magic bullets’, the use of therapeutic 
monoclonal antibodies (mAbs) against a number of 
disease targets validated this concept [1-3]. In general, 
antibody targeted therapy has much reduced toxicity than 
chemotherapy with small molecular weight chemical 
inhibitors [2]. Antibodies constitute the most rapidly 
growing class of human therapeutics and are ideal agents 
for recognizing and destroying malignant cells via the 
immune system. However, this therapeutic approach has 
been limited to surface or secreted proteins expressed by 
cancer cells [4], since antibody targeting of intracellular 
oncoproteins was previously thought to be unfeasible 
because of the intracellular location of the targets. 
As a consequence, a wide spectrum of intracellular 
oncoproteins remains unexplored in terms of antibody 
therapy approach. In 1978, Donato Alarcon-Segovia first 
discovered that antibodies could reach inside living cells 
[5]. Subsequently, the concept that intact antibodies are 
unable to gain entry into viable cells has been challenged 
experimentally as well as clinically. Over the past 2 
decades, immunologists have shown that 1) autoantibodies Oncotarget 2012; 3:  158-167 159 www.impactjournals.com/oncotarget
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Figure 1: Generation of PRL-3 specific chimeric mAb. A. A schematic diagram outlining the major steps of PRL-3 chimeric 
mAb construction. B. PRL-3 chimeric mAb recognizes EGFP-PRL-3 overexpressed in DLD-1 human colorectal cancer cells by indirect 
immunofluorescence: a, distribution of EGFP-PRL-3 in fixed DLD-1 cells (green); b, PRL-3 chimeric antibody and anti-human IgG Texas-
Red to reveal the binding to PRL-3 protein; c, merged image. Bar, 20 µm. C. Cell lysate derived from DLD-1 cells overexpressing EGFP-
PRL-3, and lysates derived from CHO stable cell lines overexpressing myc-PRL-3, myc-PRL-1, and myc-PRL-2 were analyzed by western 
blotting. PRL-3 chimeric antibody specifically recognized EGFP-PRL-3 (48 kDa, lane 1) and myc-PRL-3 (21 kDa, lane 2), but did not 
cross-react with myc-PRL-1 and myc-PRL-2 (lanes 3 and 4). Lower panel showed the equal loading of myc-PRL-3, -1, and -2 (21 kDa).  
found in the serum of autoimmune disease patients could 
bind to their respective intracellular antigens, and 2) 
immunologically mediated damage might occur when 
antibodies enter a living cell triggering apoptosis [6-8]. 
Consistently, it is demonstrated here that antibodies to 
an intracellular protein can exert therapeutic effects and 
suggest new insights to the use of therapeutic antibodies 
to include intracellular targets. 
PRL-1 (phosphatase of regenerating liver-1), 
PRL-2, and PRL-3 represent an intriguing subgroup of 
the  intracellular  protein  tyrosine  phosphatases  (PTP). 
Individual PRLs are overexpressed in a variety of 
cancer cell lines and cancer tissues when compared 
with their normal counterparts [9] and are reported to 
play multiple roles in cancer progression [10]. PRLs are 
intracellular C-terminally prenylated phosphatases. The 
localization of PRL-1 and PRL-3 to the inner leaflet of 
the plasma membrane and early endosomes was shown by 
electron microscopy (EM) immunogold labeling [11,12]. 
In  contrast,  the  mutant  forms  of  PRLs  that  lack  the 
prenylation signal are localized in nuclei [13]. PRL-3 was 
first discovered as a metastasis-associated phosphatase 
in colorectal cancer metastasis, being consistently 
overexpressed in 100% of liver metastasis samples 
taken  from  18  colorectal  cancer  (CRC)  patients  [14]. 
Overexpression of PRLs has been subsequently shown to 
have a causative role in promoting cancer metastases and 
they become potential targets for diverse cancer treatment 
[15]. As these phosphatases are intracellularly localized, 
the conventional approach using therapeutic antibodies 
would seem implausible. However, we recently reported 
an unexpected observation that mouse monoclonal 
antibodies (mAbs) against PRL-1 or PRL-3 were able 
to prevent the experimental metastasis of cancer cells 
overexpressing intracellular PRL-1 or PRL-3 [16]. 
To  extend  our  earlier  findings,  in  this  current 
study, we expanded upon the reliability of such 
targeting strategy using a newly-generated mouse/
human chimeric monoclonal PRL-3 antibody as 
a potential clinical therapeutic agent against cancer in five 
important aspects. Firstly, clinically-relevant chimeric 
antibodies instead of mouse antibodies were generated 
and characterized. Secondly, mice harboring naturally-
occurring human cancer cells that express endogenous 
PRL-3 instead of Chinese hamster ovary (CHO) cells 
expressing exogenous PRL-3 were treated. Thirdly, it was 
shown that depletion of nature killer (NK) cells abolished 
the therapeutic response and aggravated tumor burden in 
mice. Fourthly, by using paired nude versus scid mouse 
models, a crucial role for B-cells in determining the 
outcome of our antibody therapy was identified. Finally, 
using the IVIS live imaging system, fluorescent labeled Oncotarget 2012; 3:  158-167 160 www.impactjournals.com/oncotarget
antibodies were used to track their tumor binding activities 
and their working models. An evidence-based concept 
is hereby proposed for a possible approach in targeting 
intracellular oncoproteins with antibody therapies. The 
results suggest that an evaluation of a wide spectrum of 
intracellular oncoproteins (such as phosphatases, kinases, 
transcription factors, and many others) as possible targets 
for anticancer therapy may be warranted. 
RESULTS
Generation  of  PRL-3  mouse/human  chimeric 
antibodies (clone #318)
We previously reported that PRL-3 or PRL-1 mouse 
mAbs could specifically target their respective intracellular 
PRL-3 or PRL-1 phosphatase to inhibit cancer metastases 
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Figure 2. PRL-3 chimeric antibody effectively inhibits the formation of metastatic tumors formed by B16F0 cells that express 
endogenous PRL-3. A. Total cell lysates were prepared from B16F0 and B16F10 melanoma cells and analyzed by immunoblotting. 
Endogenous PRL-3 protein was readily detected in B16F0 but was almost undetectable in B16F10 cells. GAPDH was used as a loading 
control. B. A timeline of the therapeutic schedule of PRL-3 chimeric mAb administration. C, D. Mice were injected with 1 x 106 B16F0 
cells (C; n = 27) or B16F10 cells (D; n = 22), followed by the therapeutic schedule described in B. Organs were harvested, examined, and 
imaged on ~ day 17. E. Kaplan-Meier survival curves were used to compare treated and untreated B16F10 recipients. p < 0.05 was regarded 
statistically significant. n = numbers of mice per group. Oncotarget 2012; 3:  158-167 161 www.impactjournals.com/oncotarget
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Figure 3: PRL-3 chimeric mAb inhibits the formation of metastatic tumors formed by A2780 cells and HCT-116 cells 
that express endogenous PRL-3. A. Total cell lysates were prepared from HCT116-luc2, HCT116, A2780, and NCI-H460 cancer cell 
lines. Endogenous PRL-3 protein was detected in HCT116-luc2, HCT116, and A2780 cells, but not in NCI-H460. B. On day 1, nude mice 
(n = 6) were injected with 1 x 106 HCT116-luc2 cancer cells and subsequently administered with PRL-3 chimeric mAb (treated, n = 3) 
or PBS (untreated, n = 3) on day 3, followed by biweekly intravenous administrations of the PRL-3 chimeric mAb or PBS, respectively, 
for 7-weeks. Both cancer cells and antibodies were injected via tail vein. IVIS Imaging System was used to track and monitor tumor 
development in vivo. C. On day 1, nude mice were injected with 1 x 106 cancer cells and treated as described in B. Paired experiments 
(untreated/treated) were terminated when mice appeared moribund. Experiment durations are indicated on the top of each panel. D. 
Summary of results from the 101 mice used in this study, comparing the therapeutic efficacies of mouse PRL-3 (m318) or chimeric PRL-
3 (h318) in nude mice injected with three different human cancer cell lines. Fisher’s exact test was used to score the percentage of mice 
without effective treatment outcome. Red columns represent untreated mice, while black columns represent treated mice. p < 0.05 was 
regarded statistically significant. n = numbers of mice per group.Oncotarget 2012; 3:  158-167 162 www.impactjournals.com/oncotarget
in  nude  mice [16]. In an attempt to translate these 
laboratory findings to clinical setting, a mouse/human 
chimeric mAb against PRL-3 was engineered to minimize 
the potential antigenicity of the mouse mAb in human. 
Using recombinant DNA technology, we separately fused 
the constant domains of heavy or light chains of the 
human IgG1 molecule with the mouse variable regions 
of PRL-3 mAb (clone m318) by transgenic fusion of the 
immunoglobulin genes (Fig. 1A) [17,18]. The expression 
construct was transfected into Human Embryonic Kidney 
(HEK) 293T cells to produce recombinant PRL-3 chimeric 
mAb that was then harvested from the culture medium 
and further concentrated. The antigen-binding specificity 
of the PRL-3 chimeric antibody was well conserved as 
confirmed  by  indirect  immuofluorescence  on  DLD-1 
cells that overexpress exogenous EGFP-PRL-3 (Fig. 
1B)  and  western  blot  analyses  (Fig.  1C). The  PRL-3 
chimeric mAb (h318) specifically recognized both EGFP-
PRL-3 (~48 kDa) and myc-PRL-3 (~21 kDa) (Fig. 1C, 
lane 1-2) but react with neither myc-PRL-1 nor myc-
PRL-2 proteins (Fig. 1C, lane 3-4). A 50% cell Inhibitory 
Cytotoxic concentration (IC50) of the chimeric antibody 
was determined on a mouse melanoma B16F0 cell line 
that expresses endogenous PRL-3 protein. No cellular 
toxicity was observed in in vitro culture system even at 
concentrations as high as 40 µg/ml (Fig. S1), suggesting 
that the antibody itself had no adverse effect on cultured 
cells. 
PRL-3 chimeric antibody effectively inhibits the 
metastatic tumors formed by mouse cancer cells 
that express endogenous PRL-3
To find a clinically relevant animal model to treat 
PRL-3-associated cancers, dozens of cancer cell lines for 
the expression of endogenous PRL-3 protein levels were 
screened by Western blot analysis. Ideal cell line pairs for 
our animal models should present contrasting levels of 
endogenous PRL-3 and should have the ability to induce 
metastatic tumors in mice within short timeframes. We 
found a pair of mouse melanoma cell lines B16F0 and 
B16F10 that fulfilled these criteria. Although B16F10 cells 
are naturally more metastatic than B16F0 cells, parental 
B16F0 cells express higher levels of endogenous PRL-3 
protein than B16F10 cells (Fig. 2A), suggesting that the 
metastatic activity of B16F10 cells might be no longer 
PRL-3 dependent. When we employed an experimental 
metastatic assay [19] in which cultured cancer cells were 
introduced into the circulation of nude mice by lateral 
tail vein injection, both B16F0 and B16F10 cells rapidly 
formed multiple metastatic tumors in mice within 17 
days. This aggressive in vivo metastasis model allowed 
testing of the differences in efficacy between ‘treated’ 
and ‘untreated’ groups shortly after antibody therapy. On 
day 3 post-injection of PRL-3 expressing B16F0 cancer 
cells, PRL-3 chimeric antibodies were administrated 
similarly via tail veins into the ‘treated’ mice, followed 
by two subsequent administrations of the antibody per 
week (Fig. 2B). ‘Untreated’ mice were administered with 
PBS (or control ascites). On day 17, the ‘treated’ mice 
appeared more active and healthier. The metastatic tumors 
in multiple tissues were dramatically reduced in ‘treated’ 
mice (Fig. 2C, right panel). The Kaplan-Meier survival 
analysis for these B16F0 recipients will be discussed 
in a later section. In a parallel experiment, the PRL-3 
chimeric antibody had no effect in blocking metastatic 
tumors formed by B16F10 cancer cells that express low 
or undetectable level of PRL-3 protein. Hundreds of 
metastatic tumors were found in the lungs of all B16F10 
recipients, and no obvious difference was seen between 
‘untreated’ (Fig. 2D, left panel) and ‘treated’ mice (Fig. 
2D,  right  panel).  Furthermore,  Kaplan-Meier  survival 
analysis demonstrated that the PRL-3 chimeric antibody 
did  not  significantly  extend  the  life-span  for  B16F10 
recipients with a median survival of 16 days for ‘untreated’ 
and 17 days for ‘treated’ mice (Fig. 2E, p = 0.5428). 
PRL-3 chimeric antibodies effectively inhibit the 
metastatic tumors formed by human cancer cells 
that express endogenous PRL-3
In addition to the B16F0 cell line, three additional 
high PRL-3-expressing cell lines were identified: HCT116, 
a  human  colorectal  cancer  cell  line;  HCT116-luc2, a 
HCT116 cell line that was established by transducing 
lentivirus containing the luciferase 2 gene (luc2) under 
the control of human ubiquitin C promoter; and A2780, 
a human ovarian cancer cell line (Fig. 3A lanes 1-3). 
A2780 has been reported as a PRL-3 positive cell line 
previously [20]. As a negative control, we identified a 
PRL-3  negative  cancer  cell  line:  NCI-H460,  derived 
from human non-small lung cancer (Fig. 3A, lane 4). It is 
worth highlighting that regardless of PRL-3 expression, 
these four cancer cell lines could rapidly form metastatic 
tumors in nude mice within 1-2 months (Fig. 3, ‘untreated’ 
mice). The HCT116-luc2 cell line together with Xenogen’s 
in-vivo imaging system (IVIS) was used to monitor 
metastatic lung tumor formation in mice. Remarkably, 
the PRL-3 antibody could inhibit metastasis of HCT116-
luc2 cancer cells, with a clear reduction of metastatic 
lung tumors (in blue) in live imaging after 7 weeks of 
antibody therapy, compared to ‘untreated’ mice (Fig. 3B, 
right panel). Similarly, overt phenotypic differences were 
found between PRL-3 antibody ‘treated’ and ‘untreated’ 
mice at 2-month post-inoculation with HCT116 cells (Fig. 
3C, a) and at 1-month post-inoculation with A2780 cells 
(Fig. 3C, b). PRL-3 chimeric antibody-treated animals 
appeared vibrant and healthy (up to 4-months), whereas 
all ‘untreated’ mice had lost weight and were moribund. In 
parallel, NCI-H460 (PRL-3 negative cells) recipients did Oncotarget 2012; 3:  158-167 163 www.impactjournals.com/oncotarget
not respond to PRL-3 antibody treatment (Figure 3C, c). 
To compare the effectiveness of PRL-3 antibody treatment 
on tumors formed by PRL-3 positive cell lines (HCT116, 
A2780) or PRL-3 negative cell line (NCI-H460) in nude 
mice, the occurrence of lung tumor metastases observed 
in ‘treated’ and ‘untreated’ groups were scored. Mice 
with less than 40% metastases reduction after treatment 
were regarded as lacking an effective outcome. Using 
this baseline, a clear beneficial effect was seen in mice 
inoculated with PRL-3 positive (but not negative) cells. 
The  efficiency  of  both  mouse-  and  chimeric-PRL-3 
antibody therapy regimes were comparable (Figure 3D). 
Overall, these results further support the conclusion that 
the efficiency of the PRL-3 antibody treatment is tightly 
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Figure 4: B-cells are important in mediating therapeutic efficacy of PRL-3 chimeric antibody. A. Kaplan-Meier survival 
curves of treated and untreated HCT-116-injected nude and scid mice (a, b). Kaplan-Meier survival curves of treated and untreated B16F0-
injected nude and scid mice (c, d). B. Summary of results from the 151 mice used in this study, comparing the results for therapeutic 
experiments in nude and scid mice (a-d). Fisher’s exact test was used to score the percentage of mice without effective treatment indicated 
at Y-axis. Red columns represent untreated mice, while black or green columns represent mice treated with mouse mAb (m318) or chimeric 
mAb (h318), respectively. p < 0.05 was regarded statistically significant. n = numbers of mice per group.Oncotarget 2012; 3:  158-167 164 www.impactjournals.com/oncotarget
correlated with PRL-3 expression status of the cancer 
cells. 
NK cells are important in anticancer therapy
The  efficacy  of  PRL-3  chimeric  antibody  in 
inhibiting PRL-3-tumor formation observed in nude 
mice suggest that T lymphocytes may not be essential 
in this antibody therapy since nude mice lack of mature 
T  lymphocytes.  We  then  investigated  if  Fc-binding, 
cytotoxic natural killer (NK) cells might play a role in 
the PRL-3 antibody therapy as NK cells are a subset of 
cytotoxic lymphocytes that constitute a major component 
of the innate immune system. To deplete the nude mice’s 
NK  cells,  we  pre-injected  nude mice with antibodies 
against  asialo  GM-1  NK  cell-surface  glycolipid,  a 
procedure which has been shown to effectively eliminate 
NK cell activity [21, 22]. Thereafter, the above-mentioned 
procedures of the antibody therapy were repeated using 
B16F0 in these anti-asialo-GM1-injected nude mice. It 
was found that the therapeutic efficacy of our chimeric 
PRL-3 antibody was essentially lost in anti-asialo-GM-
1-injected mice (Fig. S2). In support of the anti-tumor 
role of NK cells, anti-asialo-GM1-injected nude mice 
showed more severe tumors (in black)-bearing burden 
in lung, liver, adrenal, and testis than in mice without 
NK cell inhibition. Collectively, these results indicate 
the importance of the innate immune system and 
support a role for NK cells in mediating the intracellular 
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Figure 5: PRL-3 is not detectable at the cell surface, but accumulates promptly at sites of cancer metastasis in vivo. 
A. a. A peak-shift observed in A431 cells incubated with EGF-receptor antibody (black line) compared to A431 cells without incubation of 
EGF-receptor antibody (red line). b. No peak-shift was observed in B16F0 cells incubated with PRL-3 mAb (black line) and without Ab 
(red line). c. No peak-shift was observed in B16F10 cells incubated with PRL-3 mAb (black line) and without Ab (red line). B. Nude mice 
were injected with B16F0 cancer cells, ‘treated’ mice were followed by the therapeutic schedule in Fig. 2B. Labeled PRL-3 antibodies 
were intravenously injected 1 hr before IVIS live imaging at the end of experiment. A strongly fluorescent labeled lung was evident in 
‘treated’ mice. We hypothesize that early delivery of the antibody will allow persistent attack of cancer cells to prevent them from further 
progression, resulting in micro-metastases in ‘open’ stages. As such, fluorescent labeled PRL-3 antibody can access and bind to metastatic 
lung tumors in such ‘treated’ mice. Scale bar: 200 µm. Red arrows indicate blood vessels. Oncotarget 2012; 3:  158-167 165 www.impactjournals.com/oncotarget
antibody therapeutic response. Since NK cells have been 
demonstrated to have a role in human hematopoietic stem 
cell graft rejection [22], removal of NK cells may result in 
abolishment of graft rejection of NK cell activities, leading 
to tumor engraftment more successfully; indeed, we found 
‘asialo-GM1- & PRL-3-treated’ mice were worse than 
‘untreated’ mice in terms of tumor growth (Fig. S2). 
B-cells may play a role to mediate the therapeutic 
effects of PRL-3 antibodies
To next address if B lymphocytes were also critical 
to our antibody therapy model, we compared the efficacy 
of antibody therapy between nude mice (lacking mature 
T-cells) and Severe Combined Immunodeficiency (scid) 
mice (lacking both mature T- and B-cells). These mice 
were i.v. injected with PRL-3 expressing cancer cells. In 
HCT116-injected nude mice (Fig. 4A, a: Nude-HCT116), 
Kaplan-Meier survival analysis revealed a statistically 
significant (p = 0.0013) in survival of ‘treated’ mice (16 
weeks) compared to ‘untreated’ mice (11.5 weeks). In 
contrast, in HCT116-injected scid mice (Fig. 4A, b: Scid-
HCT116), we observed that PRL-3 antibody therapy did 
not significantly (p = 0.4785) prolong the overall survival 
of Scid-HCT116 mice, with a median survival of 11-
week for ‘treated’ and 10-week for ‘untreated’ mice. To 
further confirm the importance of B cells in responding 
to antibody therapies, another PRL-3-expressing cell line 
(B16F0) was used. In B16F0-injected nude mice (Fig. 4A, 
c: Nude-B16F0), Kaplan-Meier survival analysis showed 
that  PRL-3  antibody  treatment  significantly  increased 
median survival duration by 33% (24 days for ‘treated’, 
versus 18 days for ‘untreated’; p = 0.0001). Consistently, 
in B16F0-injected scid mice (Fig. 4A, d: Scid-B16F0), 
the antibodies had no effect in ‘treated’ mice, with both 
‘untreated’ and ‘treated’ groups showing similar median 
life-span (18.5 and 18 days respectively; p = 0.4545). 
As before, the therapeutic efficacy was independent of 
antibody species, as similar results were obtained using 
either mouse or chimeric PRL-3 antibodies (Fig. 4B, 
black or green column). Collectively, the results from 
these genetic mouse models suggest that PRL-3 antibody 
therapeutic  efficacy  against  PRL-3  metastatic  tumor 
formation is dependent on host B-cell but not T cells. 
Other than antibody production, we hypothesized that 
B-cell may have additional functions; such as the secretion 
of unknown factor(s) that could facilitate the action of 
antibodies. 
PRL-3 antigen is insignificantly present at the cell 
surface
A possible mechanism of PRL-3 antibody action 
could be its binding of PRL-3 encoded cell surface 
antigen(s),  thereby  triggering  a  B-cell  and/or  NK-cell 
dependent elimination of the PRL-3 expressing cell. 
However, to date, no reports describe a cell surface 
localization of PRL-3. To address the possibility of PRL-3 
antibody binding its antigen on the cell surface, we used 
a FACS assay routinely used in cell surface labeling. As 
a positive control, anti-EGFR antibody binding of the 
EGFR-overexpressing human epidermoid carcinoma A431 
cell line was used for this assay. Incubation of A431 cells 
with anti-EGFR antibodies caused a distinct peak-shift in 
the FACS assay (Fig. 5A, a). However, no peak shift was 
observed in either B16F0 (PRL-3 positive) or B16F10 
(PRL-3 negative) cells incubated with or without anti-
PRL-3 antibody (Fig. 5A, b-c). These results implied that 
extracellular PRL-3 protein, if any, was unlikely to be the 
major cause of antibody binding. However, since immune 
system constantly battles invaders, such as bacteria and 
viruses, and cancer cells in vivo, the cancer cells could be 
destroyed and lysed to expose their intracellular proteins to 
the immune system and produce a localised inflammatory 
reaction to trigger cell death. If so, the same explanation 
may apply to PRL-3 and other intracellular oncoproteins 
as well. 
In-Vivo  Imaging  System  (IVIS)  live  imaging-
based working models
To investigate if PRL-3 mAb can bind and reach 
to PRL-3 metastatic tumors, we used fluorescent labeled 
PRL-3 mAb to track sites of metastatic tumors. It was 
observed  that  the  strong  fluorescent  labeled  PRL-3 
antibodies were concentrated at the lung filled with PRL-
3 metastatic tumors (Figure 5B), suggesting that the 
fluorescent labeled antibodies can arrive at the metastatic 
lung tumors in vivo. With the current clinical practice 
of assessing whether the cancer is Her2-positive before 
considering the Herceptin antibody therapy [23], a similar 
approach can be used for antibodies which target the PRL-
3 intracellular oncoprotein to prevent further spreading or 
relapse in PRL-3 positive cancer patients. Other than using 
PRL-3 mouse antibody to perform IHC test on cancer 
biopsy in order to identify PRL-3 positive patients, the 
IVIS live imaging system may serve as another method 
to screen PRL-3 positive cancer patients for the treatment 
using the PRL-3 chimeric antibody. 
PRL-3 chimeric antibody is likely to have broad 
applications in inhibiting PRL-3 positive cancers 
Genes  specifically  upregulated  during  tumor 
formation but poorly or not expressed in host tissues are 
particularly promising as tumor-specific targets. PRL-3 
was reported to be upregulated in multiple human cancers 
[24, 25] and was not detected in most of the mouse 
tissues (Fig. S3A). Therefore, PRL-3 fulfills the criteria 
to be validated as a biomarker and a target for anticancer Oncotarget 2012; 3:  158-167 166 www.impactjournals.com/oncotarget
Figure 6: PRL-3 protein is upregulated in lung cancers and AML. A, B. Representative immunohistochemistry (IHC) 
staining of PRL-3 expression in lung squamous cell carcinoma (A) and lung adenocarcinoma (B). Scale bar: 100 µm. C. Summary of 
the percentages of PRL-3-positive lung cancers as detected with IHC, grouped according to cancer subtypes. D. In AML bone marrow 
samples were examined by IHC, 24 out of 69 (35%) showed PRL-3 expression. Three representative images are shown. 
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therapy. We anticipate that the PRL-3 antibodies are 
likely to have broad applications to block multiple types 
of PRL-3 positive cancer spreading, especially in some 
lethal malignancies such as lung cancers and acute 
myeloid leukemia (AML) that often relapse within short 
timeframes. Amongst lung cancers, we found PRL-3 is 
overexpressed in 31% of squamous cell carcinoma and 
26% of adenocarcinoma (Fig. 6A-C), two main subtypes 
of highly recurrent non-small cell lung carcinoma 
comprising 80% of human lung cancer. We also found that 
PRL-3 is overexpressed in 35% (24 out of 69 cases) of 
AML bone marrow samples (Fig. 6D). 
DISCUSSION
PRL-3 is upregulated in numerous types of human 
cancers and is involved in their metastasis [10, 24, 25]. 
An evidence-based concept is hereby proposed for a 
possible approach in targeting intracellular oncoproteins 
with antibody therapy. Using different mouse models and 
cancer cell lines, we consistently demonstrated herein that 
antibodies to intracellular PRL-3 protein could specifically 
exert therapeutic effects. It is anticipated that the PRL-
3 chimeric antibody is likely to have broad applications 
in blocking the progression of different types of PRL-3 
positive cancers, particularly in malignancies such as lung 
cancers and acute myeloid leukemia (AML) that often 
relapse within short time frames. Therefore, therapeutic 
effects will be more apparent after treatment in acute 
cancers, when compared with ‘untreated’ PRL-3 positive 
patients.
Currently, our understanding of how PRL-3 
antibodies inhibit PRL-3-positive tumors in vivo is limited. 
Despite previously proposing several possible mechanisms 
of action based on in vitro data on how antibodies may 
access to cancer cells [16], the precise mechanism(s) 
behind these findings is still an active area of research. 
However, it is of important to note that the precise 
mechanism(s) of anti-HER2/neu antibody therapy is not 
yet understood even though the anti-HER2/neu antibody 
has been used clinically for more than a decade for treating 
breast cancers [23]. We demonstrate a lack of PRL-3 
antibody cytotoxic effect in vitro, even at high antibody 
concentrations (Fig. S1), suggesting that using in vitro cell 
culture systems to elucidate the mechanism of intracellular 
antibody therapy is not representative because the cell 
culture system is too simplified due to the limitation of a 
single cell type grown in vitro, lacking the interplay of 
complex in-vivo systems - omission of critical interactions 
with the tumor microenvironment. Nevertheless, from the 
results in this study, our reproducible observations here 
and elsewhere indicate that intracellular oncoproteins are 
viable targets for anticancer therapy. We highlight the 
following points to be considered before translating these 
results into clinical applications: 1) Antibody treatment 
efficacy is tightly correlated with the expression status of 
its antigen in cancer cells. We demonstrated here that the 
PRL-3 chimeric antibody could successfully block the 
formation of metastatic tumors derived from several 
cancer  cell  lines  (B16F0,  HCT-116,  and A2780)  that 
express intracellular PRL-3 phosphatase. The inhibition 
was specific as the antibody had no effect in blocking the 
formation of metastatic tumors derived from other cancer 
cell lines (B16F10, H460) that did not express PRL-3. Our 
previous results had demonstrated that mouse PRL-3 
antibody had no effect in inhibiting metastatic lung tumors 
formed  by  CT26  mouse  colon  cells,  another  PRL-3 
negative cancer cell line [16]. Together, the data support 
the notion that the efficiency of both mouse and chimeric 
PRL-3 antibody treatment is tightly correlated with PRL-3 
expression status of the cancer cells. If the metastatic 
property of cancer cells was not associated with PRL-3 
expression (such as B16F10, H460, CT26 cell lines), the 
administration of PRL-3 mAb would have no effect in 
blocking tumors formed by these PRL-3 negative cells. 
Furthermore, we previously [16] had shown that PRL-1 
mAb specifically blocks PRL-1 (but not PRL-3) metastatic 
tumors; while PRL-3 mAb specifically blocks PRL-3 (but 
not  PRL-1)  metastatic  tumors.  This  is  especially 
remarkable  because  PRL-1  and  PRL-3  share  high 
homology (76%) in protein sequence. Collectively, these 
results imply that PRL antibody therapy is highly specific 
to its antigen and does not involve cross-reactivity with 
other  non-specific  cell  surface  proteins.  2) Not all 
intracellular oncoproteins are viable targets for antibody 
therapy. Desirable anti-cancer therapeutic agents should 
specifically  target  cancer  cells  while  leaving  normal 
tissues unharmed. It should be emphasized that the PRL-3 
chimeric antibody therapy has little detectable side effect 
in nude mice as PRL-3 expression in normal tissues is not 
ubiquitous. We showed that PRL-3 protein was detected in 
only a few organs such as the spleen, brain, and pancreas 
(Fig. S3A). In contrast, PRL-2 is ubiquitously expressed 
in most of the mouse tissues (Fig. S3B). As expected, 
PRL-2 antibody therapy to PRL-2 expressing cancers was 
unsuccessful (Fig. S3C), and PRL-2 antibody-treated mice 
died  1-week  earlier  or  showed  worse  outcome  than 
‘untreated’ mice, likely due to the side effect of anti-
PRL-2 antibody causing normal PRL-2-expressing tissues 
to be targeted by the PRL-2 antibodies. Thus, the choice of 
a good therapeutic target should be tumor-specific to avoid 
harming host normal tissues. 3) NK cells of the innate 
immune system are involved.  To  understand  if  innate 
immune system was involved in antibody therapy, we 
intravenously injected anti-asialo-GM1 antibody via tail 
vein into nude mice to deplete NK cells, which are a type 
of cytotoxic lymphocytes that constitute a major 
component of the innate immune system. In the absence of 
NK cell activity, we found that anti-PRL-3 antibody lost 
therapeutic efficacy. Furthermore, tumor-engraftment was 
dramatically enhanced (Fig. S2), indicating that NK cells 
normally play a critical role in graft-rejection for Oncotarget 2012; 3:  158-171 168 www.impactjournals.com/oncotarget
implantation of foreign cells. Evidence also suggests that 
NK cells play an important part in the destruction of 
incipient tumors [21]. 4) Antibody-dependent cellular 
cytotoxicity  (ADCC)  may  also  be  involved.  The  best 
characterized mechanism of antibody therapy is antibody-
dependent cellular cytotoxicity (ADCC). In ADCC, 
antibodies bind to specific cell surface antigens and trigger 
an Fc-mediated immune response involving cytotoxic 
CD8  T-cells,  complement  activation,  and/or  NK  cell 
activity. Although we did not observe any peak-shifts in 
our FACS analysis of PRL-3 cell surface antigen in neither 
PRL-3-expressing B16F0 cells nor PRL-3 low-expressing 
B16F10 cells, we could not rule out a possibility that these 
cancer cells were under abnormal inflammatory pressure, 
which may cause the destruction of cancer cells releasing 
their  intracellular  protein.  This  enables  the  antigen-
antibody reaction to trigger specific immune response with 
lymphocytes removing these cancer cells. Alternatively, in 
vivo, cancer cells are under hypoxic stress steps and serum 
deprivation, conditions that arrest cells at G and G phases 
[26]. It is possible that these conditions may cause release 
of intracellular antigens for antibody recognition. If so, 
other intracellular oncoproteins may also encounter the 
similar situations, and could therefore be similarly targeted 
with antibody therapy. 5) The adaptive immune system is 
important in eliciting mAb therapeutic effect. We observed 
a therapeutic effect only in nude mice but not in scid mice 
in  our  antibody  therapy  experiments.  The  major 
differences between nude and scid mice are that nude mice 
are T-cell deficient, but have functional IgM antibodies 
and B cells, whereas scid mice have no functional adaptive 
immune system including B-cells, T-cells, IgM and other 
antibodies. Both nude and scid mice, however, have intact 
innate immune systems including normal NK cell and 
complement activity. The positive response seen only in 
nude (but not in scid) mice, indicates that mature B cells 
(but not T cell), and possibly IgM/serum antibodies, are 
more important and might co-ordinate with the innate 
immune system in generating the anticancer response 
observed here. Since the PRL-3 antibodies here were 
exogenously introduced into mice, we hypothesize that the 
requirement of B-cells for antibody activity might be due 
to an alternative role for B-cell in the antibody response, 
possibly  via  secretion  of  unidentified  factor(s)  that 
modulates the host response. Herein, we emphasize that 
the intricate interplay of innate and acquired immune 
system is crucial for the anticancer efficacy of a chimeric 
antibody targeting intracellular PRL-3 oncoprotein. 6) 
Antibody  therapy  against  intracellular  oncoprotein  is 
clinically relevant. To  generate  an  aggressive  cancer 
model for antibody treatment, we directly injected 1 
million cancer cells into mouse blood circulation. Given 
that the total blood volume in nude mouse is 8% of its 
body weight (8% of ~19g = 1.5ml), this translates to the 
introduction of approximately 6.7 x 105 cancer cells/mL of 
blood.  Remarkably,  despite  such  a  high  cancer  cell 
concentration in blood, we observed overt therapeutic 
benefit, despite delaying antibody treatment until 3-day 
post-cancer cell injection. In light of this, we hypothesize 
that a few injections of chimeric antibody could 
significantly reduce the recurrence rate of operable tumors, 
as the PRL-3 antibodies continue to act on any remaining 
circulating cancer cells [27] by removing non-visible 
incipient tumors after surgical resection. 
Herein,  we  have  conducted  the  first  chimeric 
antibody study in targeting an intracellular oncoprotein 
(PRL-3, in this case) for cancer therapy in mice. We also 
recently proposed that other intracellular oncoproteins 
could also be targeted with antibody therapy and/or 
vaccination [28]. The lack of observable side effects in 
nude mice upon PRL-3 antibody therapy further alludes to 
its potential clinical benefits. As with the current clinical 
practice of assessing the Her2-status of cancers before 
considering Herceptin antibody therapy [29], a similar 
approach could be used for antibody targeting PRL-3 
intracellular oncoprotein to circumvent further spreading 
or relapse in PRL-3 positive cancer patients. Importantly, 
our data prompts an evaluation of a wide spectrum of 
tumor-specific  intracellular  oncoproteins  as  possible 
targets for anti-cancer mAb therapy, thus realizing the full 
potential of antibodies as ‘magic bullets’. 
MATERIALS AND METHODS
Generation  of  specific  PRL-3  human/mouse 
chimeric mAb (clone #318)
To generate PRL-3 chimeric mAb, total RNA was 
extracted from 6 x 106 hybridoma cells (clone #318) [17] 
using the RNeasy Mini Kit (QIAGEN, Cat #74104). The 
RNAs were then reverse-transcribed into cDNA using 
SuperScript II RNase H (Invitrogen, Cat 18064-014). The 
resulting total cDNAs were used as templates to generate 
the  ‘universal  variable  region’.  The  Ig-Primer  Sets 
(Novagen, Cat #69831-3) were designed for amplification 
by PCR (950C-40C-720C,  30  cycles)  to  specifically 
amplify of immunoglobulin (Ig) variable region of light- 
and heavy-chain cDNAs from mouse sources. The PCR 
fragments were cloned into the PCRII-TOPO-Vector with 
a TA cloning kit (Invitrogen, Cat #45-0640). Appropriately 
designed oligonucleotide primer sets enable these variable 
region of light- and heavy-chain cDNAs to be cloned into 
the respective sites of a human IgG1 constant region 
expression vector-pCMV-human IgG1[18] to join the 
mouse variable region with the human IgG1 constant 
region. The complete construct was transiently transfected 
into 293T cells cultured in media supplemented with ultra-
low IgG FBS (Gibco, 16250-078). The chimeric mAb 
was subsequently harvested from the culture supernatant 
and concentrated up to 40 folds with centrifugal filter Oncotarget 2012; 3:  158-171 169 www.impactjournals.com/oncotarget
devices  (Millipore,  Cat  #UFC900596).  The  chimeric 
mAb  was  then  tested  for  its  specificity  by  indirect 
immunofluorescence (IF) and Western blot analysis.
Cell lines and cell culture
HCT116 (CCL-247) human colorectal carcinoma 
cell line, NCI-H460 (HTB-177) human non-small lung 
cancer cell line, A431 (CRL-1555) human epidermoid 
carcinoma cell line, B16F0 (CRL-6322), and B16F10 
(CRL-6475) mouse melanoma cell lines were purchased 
from  the  American  Type  Culture  Collection  (ATCC, 
Manassas, VA). A2780 (Cat #93112519) human ovarian 
cancer cell line was purchased from ECACC, UK. Cells 
were grown in appropriate media recommended by the 
suppliers. 
Western blot analysis
Generation of mouse PRL-3 monoclonal antibody 
and Western blot procedures have been described 
previously [17]. GAPDH antibody was from Millipore 
(Bedford,  MA).  Donkey  anti-human  HRP-conjugated 
secondary antibody (Cat #709035149) was obtained from 
Jackson ImmunoResearch Laboratories (West Baltimore, 
PA).
Experimental Metastatic Assay in mice [20]
1 x 106 cancer cells were injected into the circulation 
of eight-week old nude mice (Jackson Labs, USA) via the 
tail vein on day 1. Chimeric PRL-3 mAbs (h318) or mouse 
PRL-3 mAbs (m318) were subsequently injected into the 
tail vein, with the first antibody administration was carried 
on day 3 post-cancer cell injection (the latest time we can 
delay for treatment), followed by two administrations per 
week. For control untreated group, PBS was administrated 
via tail vein. All animal studies were approved by the 
Institutional Review Board (IRB) of the Institute of 
Molecular and Cell Biology (IMCB), in strict compliance 
with rules and policies of the Animal Facility Center of 
The Agency for Science, Technology and Research (A* 
STAR), Singapore. 
Depletion of NK cells
Anti-asialo GM1 anti-serum (raised in rabbit) was 
purchased  from  Wako  Pure  Chemical  Industries,  Ltd 
(Osaka  540-8605,  Japan).  The  anti-asialo  GM1  anti-
serum (50 µl) was injected into the circulation of eight-
week old nude mice (Jackson Labs, USA) via the tail vein 
24 h before 3 x 105 cancer cells were injected into the 
circulation of the nude mice. Subsequent steps of antibody 
therapy were carried out as described earlier.
Antibody labeling and IVIS live imaging
HCT116-luc2  Bioware Ultra cell line, obtained 
from Caliper Life Sciences, Inc. (Hopkinton, MA), was 
established  by  using  HCT116  human  adenocarcinoma 
cells (ATCC, CCL-247T) stably transduced with lentivirus 
containing luciferase 2 gene under the control of human 
ubiquitin C promoter (pGL4 luc2). 1 x 106 HCT116-luc2 
cancer cells were injected into tail veins of 8-week old 
nude mice. Antibody was then injected into ‘treated’ mice 
via tail veins on day 3, follow by two antibody injections 
per week. After 7-week treatment, purified PRL-3 antibody 
(by protein G/A bead) was labeled using a CF750 Dye 
Antibody Labeling Kit from Caliper Life Sciences, Inc. 
(Hopkinton, MA). Labeled antibodies were injected via 
tail vein 1 hr before live imaging. Mice are injected by an 
intraperitoneal route with a luciferin solution (200 x stock 
solution 30 mg/ml in PBS, dose of 150 mg/kg) that is 
allowed to distribute in conscious animals for about 5-15 
minutes. The mice were then placed into a clear plexiglass 
anesthesia box (supplied with 2.5-3.5% isofluorane) that 
allows unimpeded visual monitoring of the animals using 
IVIS® Spectrum Imaging System 3D Series to track and 
monitor tumor development in vivo. The results between 
‘treated’ verse ‘untreated’ mice were determined. 
FACS analysis
The human epidermoid carcinoma cell line A431 
was grown in DMEM with high glucose (4.5g/L), 
supplemented with 10% FBS and 5% antibiotic. B16F0 
and B16F10 cells were grown in RPMI, supplemented 
with 10% FBS and 5% antibiotics. Cells (5 x 106) were 
dislodged from the dishes with non-enzymatic pre-
warmed cell dissociation solution (Sigma, Cat #c-5914) 
and transferred to 5 ml polystyrene tubes and washed once 
with complete medium. The cells were then incubated with 
1 µl EGFR (Genetech, USA) or 5 µl PRL-3 mouse primary 
antibodies in 100 µl of complete medium for 1 h at room 
temperature (RT). Cells were agitated every 15 minutes 
to prevent clumping. Cells were then washed twice with 
complete medium and incubated for 1 h at RT with goat 
anti-mouse AlexaFluor 546 antibody (Invitrogen, USA), 
washed, and re-suspended in 1 ml complete medium 
prior to analysis using BD FACS Caliber. Raw data was 
processed using WinMDI ver2.8 software. 
Histopathologic  Analyses  Using 
Immunohistochemistry (IHC)
Human lung cancer tissue arrays 009-01-004, CC00-
01-006 and CC04-01-CC04 were purchased from Cybrdi, 
Inc. (Rockville, MA). Human AML bone marrow samples 
were obtained from the National University Hospital-Oncotarget 2012; 3:  158-171 170 www.impactjournals.com/oncotarget
National  University  of  Singapore  (NUH-NUS) Tissue 
Repository with approval of the Institutional Review 
Board (IRB) of NUH-NUS for research use. The use of all 
human tissue samples including commercial samples were 
approved by IRB of IMCB. Dako EnVisionTM Systems K 
1395 (Carpinteria, CA) was used to perform IHC analysis 
[16,17]. 
Statistical analysis
The  Kaplan-Meier  method  was  used  to  compare 
survival time between ‘treated’ and ‘untreated’ mice 
groups. Fisher’s exact test was used to analyze the 
association of treatment response to treatment groups. A 
p value < 0.05 was considered statistically significant. 
Graphpad Prism4 software package (La Jolla, USA) was 
used for all statistical calculations.
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